Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 53 min 51 sec ago

Caldera Medical Announces FDA Clearance for New Generation of Vertessa(R) Lite Polypropylene Mesh for Sacrocolpopexy

Fri, 06/26/2015 - 16:06
Device Maker Continues to Broaden Product Portfolio with a Unique Blue, Lightweight, Flexible-Yet-Strong Mesh for Sacrocolpopexy AGOURA HILLS, Calif.--(Healthcare Sales & Marketing Network)--Caldera Medical, a medical device company leading the developm...
Devices, Product Launch, FDA
Caldera Medical, Vertessa, sacrocolpopexy, Pelvic Organ Prolapse

EYLEA(R) (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion

Fri, 06/26/2015 - 13:58
TARRYTOWN, N.Y., June 26, 2015 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA® (aflibercept) Inj...
Biopharmaceuticals, Ophthalmology, Regulatory
Regeneron Pharmaceuticals, EYLEA, aflibercept, retinal vein occlusion

Spacelabs Reinvents Medical Telemetry with Release of XTR

Thu, 06/25/2015 - 14:56
SNOQUALMIE, Wash.--(Healthcare Sales & Marketing Network)--Spacelabs Healthcare today announced the release of the newest medical telemetry solution on the market – XTR – Xhibit Telemetry. As the original innovators of telemetry with roots in the NASA s...
Devices, Monitoring, Cardiology, Product Launch
Spacelabs, XTR, Xhibit Telemetry, ECG

Pulmatrix Appoints William Duke, Jr., as Chief Financial Officer

Thu, 06/25/2015 - 14:52
LEXINGTON, Mass., June 25, 2015 -- (Healthcare Sales & Marketing Network) -- Pulmatrix, Inc. (PULM) announced today the appointment of William Duke, Jr., as chief financial officer. Mr. Duke previously served as chief financial officer of Valeritas, Inc.,...
Biopharmaceuticals, Drug Delivery, Personnel
Pulmatrix, iSPERSE, cystic fibrosis, chronic obstructive pulmonary disease

Aegerion Pharmaceuticals Appoints Gregory Perry as Chief Financial Officer

Thu, 06/25/2015 - 14:47
CAMBRIDGE, Mass., June 25, 2015 -- (Healthcare Sales & Marketing Network) -- Aegerion Pharmaceuticals, Inc. (AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare d...
Biopharmaceuticals, Personnel
Aegerion Pharmaceuticals

Autonomic Technologies Completes Transatlantic Series D Financing of $43.2M

Thu, 06/25/2015 - 12:10
REDWOOD CITY, CA--(Healthcare Sales & Marketing Network) - Autonomic Technologies®, Inc. (ATI®), developer and manufacturer of Pulsante™, a microstimulator to treat severe headaches, today announced the closing of its series D round of financing fo...
Devices, Neurology, Venture Capital
Autonomic Technologies, Pulsante, microstimulator, Neurostimulation

Medical Device Firm Advanced Cooling Therapy Receives FDA De Novo Clearance for Esophageal Cooling Device to Cool and Warm Patients

Wed, 06/24/2015 - 14:42
CHICAGO--(Healthcare Sales & Marketing Network)--Emerging medical device firm Advanced Cooling Therapy has received a de novo clearance from the US Food and Drug Administration (FDA) to market its first product, the Esophageal Cooling Device (ECD), in the ...
Devices, FDA
Advanced Cooling Therapy, Esophageal Cooling Device

ViraTherapeutics Raises €3.6 Million in the First Closing of a Series A Financing Round to Advance its Novel Oncolytic Virus Platform

Wed, 06/24/2015 - 14:34
Funds will be used to progress ViraTherapeutic's lead product VSV-GP towards clinical proof of concept in patients with solid tumors. INNSBRUCK, Austria, June 24, 2015 -- (Healthcare Sales & Marketing Network) -- ViraTherapeutics GmbH (ViraT), a privat...
Biopharmaceuticals, Oncology, Venture Capital
ViraTherapeutics, Vesicular Stomatitis Virus

Histogenics Corporation Announces Appointment of New Chief Financial Officer

Mon, 06/22/2015 - 16:30
Experienced Financial and Investment Banking Executive Jonathan Lieber to Join Executive Team WALTHAM, Mass., June 22, 2015 -- (Healthcare Sales & Marketing Network) -- Histogenics Corporation (Histogenics) (HSGX), a regenerative medicine company focuse...
Devices, Regenerative Medicine, Orthopaedic, Personnel
Histogenics, NeoCart

Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma

Mon, 06/22/2015 - 16:24
The FDA approval follows similar recognition for ImMucin from the EMA. This approval demonstrates the FDA's acknowledgement of an existing medical need for treatment of multiple myeloma and ImMucin's potential in treating this type of cancer NESS ZIONA,...
Biopharmaceuticals, Oncology, FDA
Vaxil Bio, ImMucin, multiple myeloma

OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd.

Fri, 06/19/2015 - 13:38
Strategic acquisition to combine medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic diseases PETACH TIKVA, Israel, June 19, 2015 -- (Healthcare Sales & Marketing Network) -- OphthaliX Inc. (OPLI),...
Biopharmaceuticals, Ophthalmology, Mergers & Acquisitions
OphthaliX, Can-Fite BioPharma, Vision Systems Ltd

Sorin Group Announces European Launch of KORA 250, the World’s Smallest Full Body MRI Conditional Pacing System

Fri, 06/19/2015 - 13:29
Equipped with the proprietary Automatic MRI mode and Sleep Apnea Monitoring, the KORA 250 pacemaker family is designed to improve patient outcome while driving efficiency in practice. MILAN--(Healthcare Sales & Marketing Network)--Sorin Group (SRN.MI), ...
Devices, Cardiology, Radiology, Product Launch
Sorin Group, KORA 250, pacemaker

Lumenis to be Acquired for Approximately $510 Million, $14.00 Per Share, in Cash

Thu, 06/18/2015 - 14:08
YOKNEAM, Israel, June 18, 2015 -- (Healthcare Sales & Marketing Network) -- Lumenis Ltd. (LMNS), the world's largest energy-based medical company for surgical, ophthalmology and aesthetic applications, announced today that it has signed a definitive agreem...
Devices, Surgery, Ophthalmology, Mergers & Acquisitions
Lumenis, XIO Group

Advanced Cell Diagnostics Completes $22 Million Series C Equity Financing

Thu, 06/18/2015 - 13:59
Proceeds Will Accelerate Commercialization and Launch of New Technology Platforms HAYWARD, California, June 18, 2015 -- (Healthcare Sales & Marketing Network) -- Advanced Cell Diagnostics, Inc. (ACD), a world leader in the field of in situ nucleic acid...
Diagnostics, Venture Capital
Advanced Cell Diagnostics, RNAscope

Autonomic Technologies(R) Announces 200 Cluster Headache Patients Implanted With the Pulsante(TM) Microstimulator

Thu, 06/18/2015 - 13:52
Pulsante Microstimulator -- A New Frontier in Neuromodulation MONTREAL, QC--(Healthcare Sales & Marketing Network) - Autonomic Technologies® announces 200 patients have been implanted to date with the Pulsante™ SPG Microstimulator. The Pulsante SPG ...
Devices, Neurology
Autonomic Technologies, Pulsante, SPG Microstimulator, neuromodulation

Dutch Hospital Acquires 1,000th Agility, Elekta's Radiotherapy Beam-shaping Technology for Treating Cancer

Thu, 06/18/2015 - 13:44
LEEUWARDEN, The Netherlands, June 18, 2015 -- (Healthcare Sales & Marketing Network) -- Radiotherapy Institute Friesland (RIF) in the Netherlands recently accepted delivery of a new Elekta Synergy® linear accelerator for cancer treatment, equipped wit...
Devices, Oncology
Elekta, Agility multileaf collimator, radiotherapy, Elekta Synergy

Allergan to Acquire KYTHERA Biopharmaceuticals

Wed, 06/17/2015 - 14:17
Complements Allergan's Existing Position in Facial Aesthetics Lead Product KYBELLA™ the First and Only Approved Non-surgical Treatment for Reduction of Submental Fullness - Enhances Allergan's Long-term Growth Profile DUBLIN and WESTLAKE VILLAGE, ...
Biopharmaceuticals, Dermatology, Mergers & Acquisitions
Allergan, KYTHERA Biopharmaceuticals, KYBELLA

Neuravi Announces €19M ($21M) in Financing to Advance Innovative Minimally Invasive Stroke Therapy

Wed, 06/17/2015 - 14:07
GALWAY, Ireland--(Healthcare Sales & Marketing Network)--Neuravi, a company dedicated to improving clinical outcomes for stroke patients, announced today that it has completed a Series B financing of €19M ($21M) to advance the company’s minimally invasive ...
Devices, Neurology, Interventional, Venture Capital
Neuravi, EmboTrap, Revascularization Device, stroke

Centinel Spine(TM) Receives Allogeneic Bone Graft Indication For Its Anterior Lumbar Product Family

Wed, 06/17/2015 - 13:58
NEW YORK, June 17, 2015 -- (Healthcare Sales & Marketing Network) -- Centinel Spine™, Inc., (Centinel Spine) the pioneer of Stand-Alone, No-Profile®, Integrated Interbody™ fusion devices receive FDA clearance for its STALIF MIDLINE®, MIDLINE II™, ...
Devices, FDA, Neurosurgery, Orthopaedic
Centinel Spine, STALIF MIDLINE, MIDLINE II, MIDLINE II-Ti, spinal fusion

Kezar Life Sciences Closes $23M Series A Financing

Tue, 06/16/2015 - 15:30
Startup to Spin Out Assets From Amgen Subsidiary Onyx, Focus on Innovative New Treatments for Autoimmune Disorders SOUTH SAN FRANCISCO, Calif., June 16, 2015 -- (Healthcare Sales & Marketing Network) -- Kezar Life Sciences, a company focused on the dis...
Biopharmaceuticals, Venture Capital
Kezar Life Sciences, Immunoproteasome

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong